Differential Expression of MicroRNAs in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer.

OBJECTIVE Pancreatic cancer (PC) is a lethal disease with disappointing results from current treatment modalities, suggesting that novel therapeutic strategies are urgently needed. Since microRNAs (miRNAs) are important player in biology, the clinical utility of miRNAs for designing novel therapeutics is an active area of research. The objective of the present study was to examine differentially expressed miRNAs between normal and tumor tissues, and in plasma samples obtained from PC patients, chronic pancreatitis (CP) patients and healthy subjects (HC). MATERIAL AND METHODS The miRNA expression profiling using formalin-fixed paraffin embedded (FFPE) tissues from normal and tumor specimens was accomplished using miRBase version 19 (LC Sciences, Houston, TX, USA). Quantitative real-time PCR (qRT-PCR) was subsequently performed in individual samples for 7 selected miRNAs. In addition, qRT-PCR was also performed for assessing the expression of 8 selected miRNAs in plasma samples. RESULTS A significant difference in the expressions of miR-21, miR-205, miR-155, miR-31, miR-203, miR-214 and miR-129-2 were found in tumor tissue samples. Lower expression of miR-214 was found to be associated with better overall survival. We also observed differential expression of 8 miRNAs in plasma samples of CP and PC patients compared to HC. Interestingly, over expression of miR-21, and miR-31 was noted in both tumor tissues and in the plasma. CONCLUSION We found deregulated expression of miRNAs that could distinguish normal from PC in two different types of samples (tissues and plasma). Interestingly, lower expression of miR-214 was found to be associated with better overall survival. Although not statistically significant, we also observed higher expression of let-7a and lower expression of miR-508 to be associated with overall better survival. We conclude that our study nicely lays the foundation for detailed future investigations for assessing the role of these miRNAs in the pathology of pancreatic cancer.

[1]  Chen Huang,et al.  Regulation of miR-155 affects pancreatic cancer cell invasiveness and migration by modulating the STAT3 signaling pathway through SOCS1. , 2013, Oncology reports.

[2]  M. Katoh.  Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases , 2014, Front. Cell Dev. Biol..

[3]  E. Giovannetti,et al.  A microRNA meta-signature for pancreatic ductal adenocarcinoma , 2014, Expert review of molecular diagnostics.

[4]  Q. Cheng,et al.  Circulating MicroRNAs as Biomarkers in Hepatocellular Carcinoma Screening , 2015, Medicine.

[5]  Juntaro Matsuzaki,et al.  Role of MicroRNAs-221/222 in Digestive Systems , 2015, Journal of clinical medicine.

[6]  K. Yamao,et al.  Small carcinoma of the pancreas is curable: New computed tomography finding, pathological study and postoperative results from a single institute , 2005, Journal of gastroenterology and hepatology.

[7]  Shadan Ali,et al.  Differential Expression of MicroRNAs in Papillary Thyroid Carcinoma and Their Role in Racial Disparity , 2015, Journal of cancer science & therapy.

[8]  Xiuqin Jiang,et al.  LPS Induced miR-181a Promotes Pancreatic Cancer Cell Migration via Targeting PTEN and MAP2K4 , 2014, Digestive Diseases and Sciences.

[9]  Weixun Zhou,et al.  MLH1 as a Direct Target of MiR-155 and a Potential Predictor of Favorable Prognosis in Pancreatic Cancer , 2013, Journal of Gastrointestinal Surgery.

[10]  Shadan Ali,et al.  Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. , 2010, American journal of translational research.

[11]  Jun Yu Li,et al.  miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma , 2014, Nature Communications.

[12]  F. Yu,et al.  Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer , 2015, PloS one.

[13]  P. Chiao,et al.  Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer , 2015, Oncotarget.

[14]  I. Kim,et al.  Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. , 2010, International journal of radiation oncology, biology, physics.

[15]  T. Wang,et al.  XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. , 2014, Cancer letters.

[16]  K. Venkatasubbarao,et al.  A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer , 2014, PloS one.

[17]  B. Bao,et al.  Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. , 2012, Cancer research.

[18]  Han Liang,et al.  Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. , 2015, Cancer letters.

[19]  Wei Gong,et al.  Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance , 2013, Journal of experimental & clinical cancer research : CR.

[20]  M. Matboli,et al.  Prognostic and biological significance of microRNA-221 in breast cancer. , 2015, Gene.

[21]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[22]  B. Bao,et al.  Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells , 2011, Cancer Prevention Research.

[23]  Shadan Ali,et al.  Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. , 2013, American journal of cancer research.

[24]  N. Miller,et al.  A Circulating MicroRNA Signature as a Biomarker for Prostate Cancer in a High Risk Group , 2015, Journal of clinical medicine.

[25]  R. Vyzula,et al.  MiR-21, miR-34a, miR-198 and miR-217 as diagnostic and prognostic biomarkers for chronic pancreatitis and pancreatic ductal adenocarcinoma , 2015, Diagnostic Pathology.

[26]  Jian-jun Zhao,et al.  Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. , 2015, Cancer research.

[27]  B. Bao,et al.  Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. , 2015, American journal of cancer research.

[28]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[29]  Ling-yan Guo,et al.  The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: involvement of let-7a and miR-34a microRNAs , 2015, BioMetals.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[31]  K. Ohuchida,et al.  MicroRNA-203 Expression as a New Prognostic Marker of Pancreatic Adenocarcinoma , 2010, Annals of Surgical Oncology.

[32]  M. Bloomston,et al.  MicroRNAs in solid tumors. , 2009, The Journal of surgical research.

[33]  Shadan Ali,et al.  Clinical implication of microRNAs in molecular pathology. , 2013, Clinics in laboratory medicine.

[34]  Bo Zhou,et al.  MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN , 2013, Cancer Cell International.

[35]  T. Hong,et al.  MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens , 2014, Annals of surgical treatment and research.

[36]  G. Wang,et al.  The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy. , 2015, Archives of biochemistry and biophysics.

[37]  J. M. Thomson,et al.  Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein , 2013, PloS one.

[38]  S. Bojesen,et al.  MicroRNA biomarkers in whole blood for detection of pancreatic cancer. , 2013, JAMA.

[39]  S. Duffy,et al.  Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma , 2015, Clinical Cancer Research.

[40]  S. Sen,et al.  Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer , 2014, Journal of Cancer.

[41]  J. Ellwart,et al.  Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer , 2015, Targeted Oncology.

[42]  Xi Chen,et al.  Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts , 2015, Cancer science.

[43]  Shadan Ali,et al.  MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer , 2012, British Journal of Cancer.

[44]  Hsin-Yi Huang,et al.  SOX4 Transcriptionally Regulates Multiple SEMA3/Plexin Family Members and Promotes Tumor Growth in Pancreatic Cancer , 2012, PloS one.

[45]  A. Kallioniemi,et al.  Both inhibition and enhanced expression of miR‐31 lead to reduced migration and invasion of pancreatic cancer cells , 2012, Genes, chromosomes & cancer.